In a 72-hour leukemia-cell viability assay, wild-type Jurkat cells had a selinexor EC50 of 53.15 ± 3.6 nM. XPO1 C528S comparators were less sensitive. These engineered-cell findings identify a limit to response and do not establish the clinical prevalence of this mechanism. [1]
Across 26 breast cancer cell lines, selinexor inhibited growth with a reported median IC50 of 66 nM after 72 hours. Responses varied: the TNBC median was 44 nM, while the ER-positive median exceeded 1000 nM. These values describe an SRB growth assay. [2]
XPO1-dependent nuclear export in Jurkat cells
Cell-based study · Jurkat leukemia cells: parental XPO1 WT/WT, WT/C528S and C528S/C528S comparators. [1]
After 3 hours, selinexor caused nuclear accumulation of RanBP1 in wild-type cells; the C528S comparators showed little response. This functional cellular assay supports XPO1 target dependence, rather than a purified-protein binding constant.
Literature-Reported Treatment Conditions
- Treatment concentration
- Dilution series; representative imaging at 3 μM.
- Exposure duration
- 3 hours
- Method
- RanBP1 immunostaining; nuclear/cytoplasmic signal quantified by high-content imaging.
- Vehicle
- DMSO carrier control
- Co-treatment
- Single-agent selinexor.
- Reported limits
- Exact full dilution series is not transcribed from the plotted axis; no binding affinity measured.
Methods and source locations
Compound reported in the paper: Selinexor (KPT-330); Compound label in the paper: KPT-330 / selinexor
Evidence concerns the named compound in the reported models. Paper material is not an analytical validation of Adooq SKU A12582, its current lot or stereochemical purity.
Figure 2B–C; Results, Heterozygous substitution...; Methods, High content imaging of RanBP1
RanBP1 nuclear/cytoplasmic localization: Figure 2B–C; mean ± SD, N=2 for quantification; Results state at least 200 cells analyzed per condition. Cells are not independent biological replicates. — Figure 2B–C and caption; Results paragraph beginning To confirm...
Selinexor sensitivity in wild-type and C528S leukemia cells
Cell-based study · HL-60, Jurkat and K-562 parental and XPO1 C528S comparator cell lines. [1]
Wild-type cells had nanomolar viability EC50 values, whereas C528S comparators had markedly higher EC50 values. Heterozygous mutation was sufficient for reduced sensitivity in these engineered cancer-cell models.
Literature-Reported Treatment Conditions
- Treatment concentration
- Serial KPT-330 dilutions; EC50 values below are assay endpoints, not treatment concentrations.
- Exposure duration
- 72 hours
- Method
- CellTiter 96 AQueous viability readout normalized to DMSO.
- Vehicle
- DMSO
- Co-treatment
- Single-agent selinexor.
- Reported limits
- Full concentration schedule not transcribed; final DMSO percentage and compound purity not stated in the reviewed assay section.
Methods and source locations
Compound reported in the paper: Selinexor (KPT-330); Compound label in the paper: KPT-330 / selinexor
Evidence concerns the named compound in the reported models. Paper material is not an analytical validation of Adooq SKU A12582, its current lot or stereochemical purity.
Table 2; Figure 2A; Methods, Cell viability assays; Figure 1G and related Results
HL-60 viability relative to DMSO: 72-hour CellTiter 96 AQueous assay, absorbance at 490 nm; four-parameter log model. Table 2 does not separately define its ± term. Figure 2A shows mean ± SD (N=3 duplicates); Methods: duplicate assays repeated at least three times. — Table 2, HL-60 row; Figure 2A caption; Methods, Cell viability assays
Jurkat viability relative to DMSO: 72-hour CellTiter 96 AQueous assay, absorbance at 490 nm; four-parameter log model. Table 2 does not separately define its ± term. Figure 2A shows mean ± SD (N=3 duplicates); Methods: duplicate assays repeated at least three times. — Table 2, Jurkat row; Figure 2A caption; Methods, Cell viability assays
K-562 viability relative to DMSO: 72-hour CellTiter 96 AQueous assay, absorbance at 490 nm; four-parameter log model. Table 2 does not separately define its ± term. Figure 2A shows mean ± SD (N=3 duplicates); Methods: duplicate assays repeated at least three times. — Table 2, K-562 row; Figure 2A caption; Methods, Cell viability assays
Breast cancer cell growth panel
Cell-based study · Twenty-six breast cancer cell lines, including 14 triple-negative breast cancer (TNBC) lines and ER-positive and HER2-positive models. [2]
Growth inhibition varied across the panel. The reported TNBC median IC50 was lower than the ER-positive median, with some ER-positive lines exceeding 1000 nM.
Literature-Reported Treatment Conditions
- Treatment concentration
- Ten concentrations based on a fivefold dilution series; reported range 0–100 μM.
- Exposure duration
- 72 hours
- Method
- Sulforhodamine B (SRB) growth assay; dose-response IC50 estimation.
- Vehicle
- DMSO
- Co-treatment
- Single-agent selinexor.
- Reported limits
- Final DMSO percentage not stated in the reviewed proliferation method. IC50 values are growth assay endpoints.
Methods and source locations
Compound reported in the paper: Selinexor (KPT-330); Compound label in the paper: KPT-330 / selinexor
Evidence concerns the named compound in the reported models. Paper material is not an analytical validation of Adooq SKU A12582, its current lot or stereochemical purity.
Figure 1 and caption; Results, Selinexor has potent antitumor efficacy...; Methods, Cell proliferation assays and Drugs and reagents
Growth inhibition in the 26-line panel: SRB after 72 hours; triplicate wells; experiments performed at least three times. Aggregate medians/ranges are those reported in main Results; no ± is attached to these summaries. — Results, Selinexor has potent antitumor efficacy... first paragraph; Figure 1; Methods, Cell proliferation assays